Regeneron Pharmaceuticals Inc (REGN) Investment Analysis:
1. Executive Summary:
Regeneron Pharmaceuticals Inc (REGN) represents a uniquely integrated biotechnology enterprise that has successfully transitioned from a high-risk discovery-stage entity into a diversified, cash-generative commercial powerhouse. The company’s core identity is defined by its "Science to Medicine" philosophy, which utilizes proprietary technology platforms to accelerate the development of fully human monoclonal antibodies. Regeneron generates revenue through a multi-faceted model primarily consisting of net product sales in the United States, significant collaboration revenue from global partnerships—most notably with Sanofi for the immunology franchise and Bayer for the ophthalmology franchise—and recurring royalty streams from ex-U.S. markets.[1, 2, 3] As of the first quarter of 2026, the company continues to demonstrate robust top-line expansion, driven by its triad of blockbuster pillars: Dupixent in immunology, the Eylea franchise in ophthalmology, and Libtayo in oncology.[1, 4, 5]
The company's core products address large and growing end markets characterized by significant unmet medical needs. Dupixent (dupilumab) is the global leader in Type 2 inflammatory conditions, with approvals spanning atopic dermatitis, asthma, and chronic obstructive pulmonary disease (COPD).[4, 5] The Eylea franchise, including the standard 2 mg dose and the newly launched 8 mg Eylea HD, maintains a dominant share in the retinal disease market, treating wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).[6, 7, 8] Libtayo (cemiplimab) serves as a cornerstone of the oncology portfolio, specifically leading in non-melanoma skin cancers.[4, 7] Regeneron's customer base is primarily composed of healthcare providers, specialized clinics, and large pharmaceutical wholesalers, with a geographic footprint that is heavily concentrated in the United States for direct sales, while leveraging partners to capture global scale.[2, 9, 10]
Physicians and patients choose Regeneron over alternatives due to the superior clinical efficacy and convenience profile of its biologics. For instance, Eylea HD allows for dosing intervals of up to 20 weeks, significantly reducing the treatment burden for patients with chronic eye diseases compared to older monthly injections.[5, 6] Similarly, Dupixent has established an unparalleled safety and efficacy record across nine indications, making it the preferred biologic for dermatologists and pulmonologists alike.[4, 11] Economically, Regeneron is entering a transformative period in mid-2026 as it completes the repayment of its development balance to Sanofi, an event that will unlock substantial incremental collaboration profits and redefine its earnings trajectory through the end of the decade.[5, 12]
INTEGRATED SCIENTIFIC LEADERSHIP
2. Business Drivers & Strategic Overview:
Revenue Drivers and Product Portfolio Mechanics
Regeneron's financial engine is powered by high-margin biologic therapies that enjoy strong competitive positioning within their respective therapeutic classes. The strategic evolution of the company has been marked by its ability to maximize the life cycle of its assets, a trend most evident in the transition from the original Eylea to Eylea HD.
- The Immunology Franchise (Dupixent): Developed in a 50/50 profit-sharing collaboration with Sanofi in the U.S., Dupixent targets the IL-4 and IL-13 receptors to inhibit the signaling pathways of Type 2 inflammation.[2, 13] With global net sales reaching $4.9 billion in Q1 2026, a 31% increase on a constant currency basis, it remains the primary growth driver for the company.[1, 14] The strategic importance of Dupixent lies in its "pipeline-in-a-drug" status, as it continues to secure label expansions for indications such as COPD and chronic spontaneous urticaria (CSU), which represent massive patient populations previously underserved by biologics.[4, 5]
- The Ophthalmology Franchise (Eylea & Eylea HD): This franchise is a critical component of Regeneron’s cash flow. While the original 2 mg Eylea faces intensifying competition and impending biosimilar entry in 2027, the high-dose Eylea HD (8 mg) is strategically positioned to defend the company's market share.[3, 15] Eylea HD offers a higher concentration of the active drug, enabling extended durability and less frequent physician visits—a primary choosing factor for patients.[6, 16] In the U.S., Regeneron records all sales and shares profits with Bayer, while ex-U.S. sales are recorded by Bayer, from which Regeneron receives a share of net profits.[3, 17]
- The Oncology Portfolio (Libtayo): Libtayo is a fully human PD-1 inhibitor that has carved a niche in cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC), where it is often the preferred first-line immunotherapy.[5, 7, 18] Regeneron acquired exclusive global rights to Libtayo from Sanofi in 2022, allowing it to retain 100% of the economics for this asset.[18] The company is currently investigating Libtayo in combination with novel candidates like fianlimab (LAG-3) to move into larger indications such as metastatic melanoma.[13, 19]
Moat Analysis: The VelociSuite Advantage
Regeneron’s competitive advantage, or economic moat, is rooted in its proprietary R&D infrastructure, which creates high barriers to entry for competitors.
- Intellectual Property and Discovery Scale: The VelociSuite platform (VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi) allows Regeneron to generate optimized human antibodies at a speed and success rate that outpaces traditional biotech methods.[9, 20] VelocImmune, in particular, uses genetically modified mice with humanized immune systems to produce antibodies that require minimal engineering before entering clinical trials, reducing the risk of immunogenicity.[20]
- Human Genetics Integration: Through the Regeneron Genetics Center (RGC), the company has sequenced the exomes of over 2 million people, linking genetic variants to medical outcomes.[4] This data-powered insight allows Regeneron to identify and validate targets before clinical investment, a "de-risking" mechanism that enhances its R&D productivity.[4, 21]
- Manufacturing and Scale: Unlike many peers who outsource production, Regeneron maintains large-scale, in-house biologics manufacturing facilities. This vertical integration provides cost advantages, ensures supply chain resilience, and allows for the rapid scale-up of new launches, such as Eylea HD.[2, 9, 11]
- High Switching Costs: In the treatment of chronic conditions like macular degeneration or severe asthma, patients who are stabilized on a specific biologic are rarely switched to alternatives due to the risk of disease progression. This physician and patient inertia creates a durable "sticky" revenue stream for established brands like Eylea and Dupixent.[2]
TAM and Market Opportunity Analysis
Regeneron’s strategy involves targeting high-prevalence diseases where its technology can provide a differentiated clinical profile. The company estimates its current and pipeline programs address over $200 billion in combined market opportunities.[4]
| Therapeutic Area |
Key Asset |
Estimated Global TAM / Current Market Sales |
Prevalence / Opportunity Insight |
| Immunology |
Dupixent |
$20B+ (Annualized Sales) |
Treats 1.4M patients; expanding into COPD [4, 14] |
| Ophthalmology |
Eylea HD |
~$11B (2026 Forecast) |
Growth driven by aging global population [22] |
| Myasthenia Gravis |
Cemdisiran |
~$5.0B (2025 estimate) |
~85,000 U.S. patients; high unmet need [18] |
| PNH |
C5 Combo |
~$2.5B (2025 estimate) |
Targeted launch for 2028 [18] |
| Obesity |
Olatorepatide |
$100B+ (Long-term) |
Global Phase 3 results showed 19% weight loss [12] |
Competitive Landscape
Regeneron operates in a fiercely competitive environment against some of the world's largest pharmaceutical companies.
- Ophthalmology: The primary competitor is Roche/Genentech’s Vabysmo, which has gained significant market share since its 2022 launch due to its dual VEGF/Ang-2 inhibition.[3, 16] While Vabysmo's trajectory slowed slightly in late 2025, it remains a formidable threat to Eylea's dominance.[8, 16] Additionally, the imminent entry of aflibercept biosimilars in early 2027 from firms like Samsung and Sandoz will likely force a pricing contraction in the 2 mg segment, making the successful conversion to Eylea HD the company's most important tactical priority.[3, 15, 23]
- Immunology: Dupixent is currently "holding ground" effectively, maintaining 30%+ growth despite the launch of competitive IL-13 and JAK inhibitors.[1, 2] Its broad label and long-term safety data provide a "safety moat" that newer competitors struggle to breach.
- Oncology: In the PD-1 space, Libtayo is "holding" its lead in non-melanoma skin cancer but remains a smaller player in the massive lung cancer market compared to Merck's Keytruda.[2, 5] Regeneron's focus on "combination therapies" is its primary strategy to gain ground in this segment.
DISCOVERY-DRIVEN DOMINANCE
3. Financial Performance & Valuation:
Latest Quarterly Performance: Q1 2026
Regeneron reported its first-quarter 2026 results on April 29, 2026, delivering a "double beat" on both revenue and earnings per share.[1, 14, 24]
- Revenue: Total revenues grew 19% year-over-year to $3.61 billion, surpassing the consensus analyst estimate of $3.45 billion.[14, 25]
- Earnings: Non-GAAP diluted EPS reached $9.47, a 15% increase from $8.22 in Q1 2025, beating the expected $9.10 by $0.37.[1, 14, 24]
- GAAP Results: GAAP net income was $727 million, down 10% YoY, impacted by $0.82 per share in Acquired In-Process R&D (IPR&D) charges and costs associated with a manufacturing interruption.[1, 26]
- Guidance Changes: Management maintained its full-year EPS guidance of $48.79 and revenue guidance of $15.75 billion.[4, 24] However, the company updated its 2026 GAAP gross margin guidance to 77%–78% (from 79%–80%) to account for actual and expected costs from a temporary manufacturing interruption in Limerick, Ireland.[11, 27, 28]
- Stock Market Reaction: Despite the beats, the stock experienced a 5.43% pre-market decline and ultimately traded down as much as 7.8% intraday on April 29.[24, 29, 30] Investors focused on the 10% decline in total U.S. Eylea franchise sales ($941M vs $1.04B in Q1 2025), perceiving the transition to Eylea HD as slower than desired despite the 52% growth in HD-specific sales.[1, 29, 30]
Segmented Financial Performance
| Revenue Stream |
Q1 2026 ($M) |
Q1 2025 ($M) |
YoY Change |
Key Performance Driver |
| U.S. Eylea HD Sales |
$468 |
$307 |
+52% |
Higher volume from demand; offset by price [1] |
| U.S. Eylea 2 mg Sales |
$473 |
$736 |
-36% |
Conversion to HD and competitive pressure [1, 17] |
| Total U.S. Retina Sales |
$941 |
$1,043 |
-10% |
Ongoing conversion; seasonality impact [1, 11] |
| Libtayo (Global) |
$438 |
$285 |
+54% |
CSCC dominance and lung cancer uptake [1, 5] |
| Sanofi Collaboration |
$1,605 |
$1,183 |
+36% |
Dupixent growth and margin improvements [1, 5] |
| Bayer Collaboration |
$287 |
$344 |
-17% |
Lower ex-U.S. net profit share [1, 28] |
| Other Revenue |
$171 |
$82 |
+109% |
Strategic collaborations and licensing [1] |
Valuation and Underlying Financial Drivers
Regeneron’s valuation is increasingly disconnected from its core financial performance, currently trading at approximately 16.5x to 17.7x its 2026 non-GAAP EPS estimates.[24, 29] For an investor, the valuation is driven by three pivotal factors:
- The Sanofi "Step-Up" (Mid-2026): The primary suppressor of Regeneron's earnings has been the development balance repayment to Sanofi. This balance reached $0.3 billion in Q1 2026 and is expected to hit zero by the end of Q2 2026.[4, 5] From Q3 2026 onward, Regeneron will receive its full share of Dupixent profits, adding an estimated $1.2 billion in annualized high-margin revenue.[5, 19] Analysts project this will cause EPS to jump from ~$44.31 in 2025 to ~$52.81 in 2027, an 18% increase.[12]
- Cash Management and Buybacks: The company maintains a "fortress" balance sheet with $15.8 billion in net cash.[5, 29] In April 2026, the board authorized a new $3 billion share repurchase program.[11, 29] This aggressive capital return strategy supports the share price and improves EPS by reducing the weighted average share count, which stood at 107.7 million diluted shares in Q1 2026.[11, 31]
- Growth Pipeline Optionality: Valuation models are currently giving minimal credit to the obesity program (olatorepatide) or the oncology combinations (fianlimab). Positive data from these "growth vectors" represents significant potential for multiple expansion.[12, 19]
Five-Year Financial Trajectory (2021–2025 Recap)
| Year |
Revenue ($B) |
Net Income ($B) |
Diluted EPS |
Gross Margin |
| 2021 |
$16.07 |
$8.08 |
$76.40 |
~88% (COVID-19 impact) [32, 33] |
| 2022 |
$12.17 |
$4.34 |
$40.51 |
~84% [32, 33] |
| 2023 |
$13.12 |
$3.95 |
$37.05 |
~85% [32, 33] |
| 2024 |
$14.20 |
$4.41 |
$40.90 |
~86% [32, 34] |
| 2025 |
$14.34 |
$4.51 |
$41.48 |
~86% [10, 34] |
Source: [7, 32, 34, 35]
VALUATION INFLECTION POINT
4. Risk Assessment & Macroeconomic Considerations:
Specific Execution and Competitive Risks
The most immediate risk to the Regeneron thesis is the Eylea HD transition execution. While HD sales are growing, they are not yet fully absorbing the decline of the 2 mg standard dose.[3, 16]
* What could go wrong: If the FDA does not approve the Eylea HD prefilled syringe (PFS) during Q2 2026, or if competitive entry from Vabysmo accelerates, the company may lose "market floor" before biosimilars arrive in 2027.[3, 11]
* Early Warning Sign: A second consecutive quarter of sequential unit demand decline for Eylea HD would be a critical signal that the brand's durability advantage is being neutralized by competitors.
* Competitive Intensity: The oncology segment remains high-risk; the decision to abandon the Phase 3 NSCLC development for fianlimab highlights that Regeneron is competing against entrenched giants like Merck in areas where differentiation is difficult.[36]
Regulatory and Legal Considerations
In April 2026, Regeneron announced a landmark Most-Favored-Nation (MFN) Pricing agreement with the U.S. government.[36]
* Mechanism: Regeneron will benchmark Medicaid prices against a group of wealthy nations and offer its cholesterol drug Praluent at reduced prices via government portals.
* The Trade-off: In exchange, the company receives three years of tariff relief and protection from future government price mandates.[36, 37] While this provides mid-term regulatory certainty, it could set a precedent that caps long-term domestic pricing power for the entire biotech sector.[37]
Customer Concentration and Demand Risks
Revenue is significantly concentrated among a few large pharmaceutical distributors. In 2025, two individual customers accounted for 87% of net trade accounts receivable.[10] Any financial instability or contractual disputes with these "Customer A" and "Customer B" entities would have an immediate impact on recognized revenue and cash collection.[10]
Balance Sheet and Industry Structure Risks
Regeneron’s capital allocation is aggressive. While the $3 billion buyback program is supportive, the company is also investing nearly $6 billion annually in R&D (roughly 41% of revenue).[38, 39] A high-interest-rate environment increases the discount rate for these long-duration R&D assets, potentially pressuring the stock's valuation multiple even if earnings grow.[37] Additionally, the industry is approaching a $300 billion "patent cliff" by 2030, meaning Regeneron must continuously launch new blockbusters just to maintain its current revenue base.[40]
What Would Most Damage the Long-Term Thesis?
The "bear case" event would be a structural failure of the VelociSuite discovery engine. If the company fails to produce a clinical successor to the Dupixent/Eylea/Libtayo triad within the next 3-5 years, the company's valuation would transition from an "innovation compounder" to a "declining royalty trust" as the 2030 patent cliff for Dupixent approaches.[2, 40]
DE-RISKED BUT COMPETITIVE
5. 5-Year Scenario Analysis:
The following scenarios analyze the potential total return for REGN through 2031, based on the fundamental drivers of the Sanofi repayment and the obesity/oncology pipeline.
Base Case: The 2027 Inflection (55% Probability)
In the base case, Eylea HD stabilizes the retina franchise at ~$5.5 billion in U.S. sales, successfully offsetting the 2 mg erosion. Dupixent continues to grow at a high single-digit rate globally, reaching peak penetration in COPD. The most critical driver is the full profit share from Sanofi starting in late 2026.
* Revenue: Grows to ~$21.5 billion by Year 5.[12, 19]
* Margins: Operating margins expand to ~38% as the development balance repayment is completed.
* Earnings: EPS reaches ~$65.00 by 2031.
* Valuation: Multiple of 18x P/E, consistent with a mature biologics leader with steady R&D output.
* Outcome: Share price of ~$1,170.
High Case: Pipeline Multi-Bagger (25% Probability)
The high case assumes the "obesity bet" pays off. Olatorepatide (REGN's weight-loss drug) achieves a best-in-class safety profile, capturing 10% of the non-incretin market. Additionally, fianlimab/Libtayo combinations become the new standard of care in first-line melanoma.
* Revenue: Grows to ~$28 billion by Year 5, driven by three new billion-dollar launches (Cemdisiran, Fianlimab, Olatorepatide).[12, 18]
* Margins: Operating leverage from high-volume launches pushes margins to 42%.
* Earnings: EPS hits ~$85.00 by 2031.
* Valuation: Multiple of 22x P/E, as REGN is re-rated alongside high-growth biopharma peers.
* Outcome: Share price of ~$1,870.
Low Case: The Biosimilar Trap (20% Probability)
The low case assumes a faster-than-expected erosion of the retina franchise. If Vabysmo continues to gain share and the Eylea HD PFS launch is delayed, U.S. retina sales could drop to ~$3.5 billion. Simultaneously, price negotiations from the MFN deal compress Dupixent margins.
* Revenue: Stagnates at ~$16 billion by Year 5.
* Margins: Compression to 30% due to pricing pressure and manufacturing costs.
* Earnings: EPS remains flat around ~$42.00.
* Valuation: Multiple of 14x P/E, reflecting a company in structural decline.
* Outcome: Share price of ~$588.
Scenario Summary Table
| Scenario |
Revenue (Year 5) |
EPS Assumption (Year 5) |
Valuation Multiple |
Current Price |
Implied Future Price |
5-Year Total Return |
Annualized Return |
Probability |
| High Case |
$28.0B |
$85.00 |
22x |
$723.50 |
$1,870 |
+158.5% |
20.9% |
25% |
| Base Case |
$21.5B |
$65.00 |
18x |
$723.50 |
$1,170 |
+61.7% |
10.1% |
55% |
| Low Case |
$16.0B |
$42.00 |
14x |
$723.50 |
$588 |
-18.7% |
-4.1% |
20% |
| Weighted |
$22.0B |
$65.40 |
18.2x |
$723.50 |
$1,228 |
+69.7% |
11.2% |
100% |
Current price: $723.50.[41] Probabilities assigned based on clinical trial success rates and historical product transition benchmarks.
STRUCTURAL EARNINGS ACCELERATION
6. Qualitative Scorecard:
- Management Alignment: 9/10 – The company is still led by its physician-scientist founders, Leonard Schleifer and George Yancopoulos. Their compensation is heavily tilted toward long-term Performance Share Units (PSUs), and their insider ownership, though not specified in percentage, is culturally synonymous with the firm's identity.[39]
- Revenue Quality: 8/10 – While highly profitable, there is a reliance on two primary therapeutic axes (Retina and Immunology) and significant partner concentration. However, the acquisition of full Libtayo rights improves the quality of oncology revenue.[10, 18]
- Market Position: 7/10 – Regeneron is currently in a "defensive" posture in the retina market against Roche, while maintaining a "winning" offensive position in immunology via Dupixent expansion.[2, 3]
- Growth Outlook: 8/10 – The mid-2026 Sanofi repayment provides a "baked-in" earnings growth driver. The pipeline in obesity and rare diseases (C5) offers significant upside optionality.[12, 19]
- Financial Health: 10/10 – With $15.8 billion in net cash and nearly $1 billion in quarterly free cash flow, Regeneron is among the most financially stable firms in the healthcare sector.[5, 29]
- Business Viability: 8/10 – The VelociSuite platform provides durable "discovery viability." The primary choke point is the biologics manufacturing process, as evidenced by the Q1 2026 Limerick interruption.[9, 11]
- Capital Allocation: 9/10 – Management has successfully balanced massive R&D reinvestment with a new $3 billion share buyback and a stable dividend ($0.94/share).[5, 29]
- Analyst Sentiment: 8/10 – Consensus is a "Moderate Buy" with a target of $878, suggesting professional peers view the recent sell-off as an attractive entry point.[29, 42]
- Profitability: 9/10 – Despite a temporary GAAP gross margin dip to 76%-77%, non-GAAP margins remain industry-leading at ~86% on net product sales.[17, 28]
- Track Record: 10/10 – Regeneron has a consistent 30-year history of creating shareholder value through internal innovation rather than value-destroying M&A.[38]
OVERALL SCORE: 8.8 / 10
SCIENTIFIC COMPOUNDER
7. Conclusion & Investment Thesis:
Regeneron Pharmaceuticals Inc (REGN) is transitioning from a period of high R&D reinvestment into a phase of accelerated earnings realization. The core investment thesis is anchored by the structural inflection point occurring in late 2026. As the Sanofi development balance is extinguished, the company's share of Dupixent profits will flow directly to the bottom line, providing a high-visibility catalyst for EPS growth that is not fully reflected in current valuation multiples. While the ophthalmology franchise faces a complex transition from Eylea to Eylea HD ahead of the 2027 biosimilar entry, the high-dose formulation's superior durability and the upcoming prefilled syringe launch provide the necessary tools to defend its multi-billion dollar cash flow.
Furthermore, Regeneron’s foray into obesity with olatorepatide and its expanding oncology combination therapies provide the "next act" for the 2030s, de-risking the eventual patent cliff of its current blockbusters. The company's fortress-like balance sheet allows it to aggressively repurchase shares at a discount, creating a "floor" for valuation. The primary risk remains clinical and regulatory execution, particularly the timing of the Eylea HD PFS and the long-term impacts of the Most-Favored-Nation pricing deal. However, for an investor focused on proprietary technology and durable biologic cash flows, Regeneron appears fundamentally positioned to outperform as its earnings power is fully unlocked.
DURABLE INNOVATION ALPHA
8. Technical Analysis, Price Action & Short-Term Outlook:
Regeneron (REGN) is currently exhibiting a bearish short-term trend, trading at approximately $723.50, which is below both its 50-day moving average of $760.43 and its 200-day moving average of $735.71.[29, 30] The stock's 7.8% drop following the Q1 2026 results suggests a breakdown of short-term support levels as investors recalibrate expectations for the Eylea HD transition. Technical indicators, including a negative MACD and an RSI below 45, point to "Strong Sell" sentiment in the immediate term.[43] However, the stock is approaching a value zone where the $15.8 billion cash position and the $3 billion buyback program are likely to provide significant support. The short-term outlook remains volatile pending the FDA decision on the Eylea HD prefilled syringe applications expected later this quarter.[11, 24]
OVERSOLD VALUE OPPORTUNITY
- Regeneron Reports First Quarter 2026 Financial and Operating ..., https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2026-financial-and-operating
- What is Competitive Landscape of Regeneron Pharmaceuticals Company?, https://portersfiveforce.com/blogs/competitors/regeneron
- REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026? - TradingView, https://www.tradingview.com/news/zacks:ed6b54070094b:0-regn-soars-28-9-in-six-months-is-there-more-upside-potential-in-2026/
- Regeneron Q1 2026 slides: Dupixent drives 19% revenue growth - Investing.com, https://www.investing.com/news/company-news/regeneron-q1-2026-slides-dupixent-drives-19-revenue-growth-93CH-4645823
- [REGN Q1 2026 Earnings Call] Regeneron Posts 19% Revenue Surge to $3.6B, DUPIXENT Hits $4.9B as Pipeline Advances with Key Approvals and Data - BigGo Finance, https://finance.biggo.com/news/US_REGN_2026-04-29
- FDA Approves Extended Dosing Interval for Regeneron's EYLEA HD (aflibercept), https://www.bigmoleculewatch.com/2026/04/14/fda-approves-extended-dosing-interval-for-regenerons-eylea-hd-aflibercept/
- Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results, https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2025-financial/
- Quarterly and 2025 Ophthalmic Revenue Roundup for Roche, Regeneron, AbbVie, Novartis, and Astellas | Market Scope, https://www.market-scope.com/pages/news/8952/quarterly-and-2025-ophthalmic-revenue-roundup-for-roche-regeneron-abbvie-novartis-and-astellas
- How Does Regeneron Pharmaceuticals Company Work? - PESTEL Analysis, https://pestel-analysis.com/blogs/how-it-works/regeneron
- [10-K] REGENERON PHARMACEUTICALS, INC. Files Annual ..., https://www.stocktitan.net/sec-filings/REGN/10-k-regeneron-pharmaceuticals-inc-files-annual-report-a7ade23aa2b7.html
- Regeneron Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat, https://www.marketbeat.com/instant-alerts/regeneron-pharmaceuticals-q1-earnings-call-highlights-2026-04-29/
- Regeneron: EPS Set to Jump 18% in 2027 as Obesity Bet Reframes the Investment Case | TIKR.com, https://www.tikr.com/blog/regeneron-eps-set-to-jump-18-in-2027-as-obesity-bet-reframes-the-investment-case
- Regeneron at Barclays Healthcare Conference: Strategic Pipeline Insights - Investing.com, https://www.investing.com/news/transcripts/regeneron-at-barclays-healthcare-conference-strategic-pipeline-insights-93CH-4552529
- Regeneron Pharmaceuticals Q1 2026 Earnings Report - MarketBeat, https://www.marketbeat.com/earnings/reports/2026-4-29-regeneron-pharmaceuticals-inc-stock/
- Media Statement - February 11, 2026 - Regeneron Provides Update on Patent Litigation Against Samsung, https://investor.regeneron.com/static-files/d6e3d6a3-2adc-43f6-9704-8bc555857e83
- A sales turnaround for Regeneron's Eylea franchise will have to wait at least another quarter, https://www.fiercepharma.com/pharma/turnaround-regenerons-eylea-will-have-wait-least-another-quarter
- Regeneron (REGN) Q1 2026 Earnings Transcript | The Motley Fool, https://www.fool.com/earnings/call-transcripts/2026/04/29/regeneron-regn-q1-2026-earnings-transcript/
- REGN Corporate Presentation - Jan 2026, https://investor.regeneron.com/static-files/34bd3814-ec41-4433-8472-1e866a858c18
- Regeneron Stock: FDA Approval, Pricing Deal, and a Phase 3 Win in the Same Week, https://www.tikr.com/blog/regeneron-stock-fda-approval-pricing-deal-and-a-phase-3-win-in-the-same-week
- Regeneron Antibody Research & Medicines, https://www.regeneron.com/science/technology/antibodies
- Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026, https://investor.regeneron.com/news-releases/news-release-details/regeneron-report-first-quarter-2026-financial-and-operating/
- Eylea Market Report 2026 - Research and Markets, https://www.researchandmarkets.com/reports/5792953/eylea-market-report
- Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar, https://www.sandoz.com/us-en/news/sandoz-reaches-agreement-with-regeneron-resolving-all-patent-litigation-related-to-its-US-aflibercept-biosimilar/
- Earnings call transcript: Regeneron Q1 2026 beats estimates, stock dips - Investing.com, https://www.investing.com/news/transcripts/earnings-call-transcript-regeneron-q1-2026-beats-estimates-stock-dips-93CH-4645585
- Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say - April 29, 2026, https://www.zacks.com/stock/news/2910663/regeneron-regn-reports-q1-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2910663
- Regeneron Reports First Quarter 2026 Financial and Operating Results, https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2026-financial-and-operating/
- Regeneron Q1 2026 revenue rises 19% to $3.6B | REGN 8-K Filing - Stock Titan, https://www.stocktitan.net/sec-filings/REGN/8-k-regeneron-pharmaceuticals-inc-reports-material-event-39e5f132fe01.html
- Regeneron anticipates an EYLEA HD prefilled syringe decision this quarter while updating 2026 GAAP gross margin to 77%-78% - Seeking Alpha, https://seekingalpha.com/news/4581908-regeneron-anticipates-an-eylea-hd-prefilled-syringe-decision-this-quarter-while-updating-2026
- Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Quarterly Earnings Results, https://www.marketbeat.com/instant-alerts/regeneron-pharmaceuticals-nasdaqregn-announces-quarterly-earnings-results-2026-04-29/
- Regeneron Pharmaceuticals (NASDAQ:REGN) Trading Down 7.8 ..., https://www.marketbeat.com/instant-alerts/regeneron-pharmaceuticals-nasdaqregn-trading-down-78-heres-what-happened-2026-04-29/
- Form 10-Q for Regeneron Pharmaceuticals INC filed 04/29/2026, https://investor.regeneron.com/static-files/72bf8e5a-f760-4966-ad55-2baac7d55fb9
- Regeneron Pharmaceuticals Inc (NASDAQGS:REGN) Basic EPS (Cont. Ops), https://ng.investing.com/pro/NASDAQGS:REGN/explorer/eps_basic_cont
- Regeneron Pharmaceuticals Net Income 2012-2025 | REGN - Macrotrends, https://www.macrotrends.net/stocks/charts/REGN/regeneron-pharmaceuticals/net-income
- Regeneron Pharmaceuticals (NasdaqGS:REGN) - Earnings & Revenue Performance, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-regn/regeneron-pharmaceuticals/past
- Regeneron Pharmaceuticals Revenue 2012-2025 | REGN - Macrotrends, https://www.macrotrends.net/stocks/charts/REGN/regeneron-pharmaceuticals/revenue
- Regeneron Reports First Quarter 2026 Financial and - GlobeNewswire, https://www.globenewswire.com/news-release/2026/04/29/3283560/0/en/regeneron-reports-first-quarter-2026-financial-and-operating-results.html
- Regeneron Pharmaceuticals, Inc. Stock Price: Quote, Forecast, Splits & News (REGN) - Perplexity, https://www.perplexity.ai/finance/REGN?comparing=REGN,ALNY,RLAY,ERAS,SMMT,INSM
- JP Morgan Healthcare Conference - Regeneron Investor Relations, https://investor.regeneron.com/static-files/afaee510-5a11-44df-ad2b-c953a55cd65e
- Regeneron details 2026 votes and 2025 results | REGN Proxy Statement - Stock Titan, https://www.stocktitan.net/sec-filings/REGN/def-14a-regeneron-pharmaceuticals-inc-definitive-proxy-statement-bf14e8304b0a.html
- 3 Biotech Stocks That Could Benefit from the Patent Cliff - MarketBeat, https://www.marketbeat.com/originals/3-biotech-stocks-that-could-benefit-from-the-patent-cliff/
- REGN Stock Price Quote & News - Regeneron - Robinhood, https://robinhood.com/stocks/REGN
- REGENERON PHARMACEUTICALS (REGN) Forecast, Price Target & Analyst Ratings, https://www.chartmill.com/stock/quote/REGN/analyst-ratings
- REGN Technical Analysis, RSI and Moving Averages - Investing.com, https://www.investing.com/equities/regeneron-phar.-technical